These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
656 related articles for article (PubMed ID: 15544357)
1. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition. Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357 [TBL] [Abstract][Full Text] [Related]
2. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition. Sutherland JS; Bhakta V; Filion ML; Sheffield WP Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704 [TBL] [Abstract][Full Text] [Related]
3. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin. Sutherland JS; Bhakta V; Sheffield WP Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606 [TBL] [Abstract][Full Text] [Related]
4. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II. Sutherland JS; Bhakta V; Sheffield WP Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786 [TBL] [Abstract][Full Text] [Related]
5. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition. Roddick LA; Bhakta V; Sheffield WP BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622 [TBL] [Abstract][Full Text] [Related]
6. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance. Cunningham MA; Bhakta V; Sheffield WP Thromb Haemost; 2002 Jul; 88(1):89-97. PubMed ID: 12152684 [TBL] [Abstract][Full Text] [Related]
7. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins. Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677 [TBL] [Abstract][Full Text] [Related]
8. Role of the P6-P3' region of the serpin reactive loop in the formation and breakdown of the inhibitory complex. Plotnick MI; Schechter NM; Wang ZM; Liu X; Rubin H Biochemistry; 1997 Nov; 36(47):14601-8. PubMed ID: 9398179 [TBL] [Abstract][Full Text] [Related]
9. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity. Gierczak RF; Bhakta V; Xie M; Sheffield WP J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905 [TBL] [Abstract][Full Text] [Related]
10. Development of a novel recombinant serpin with potential antithrombotic properties. Hopkins PC; Crowther DC; Carrell RW; Stone SR J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836 [TBL] [Abstract][Full Text] [Related]
11. Role of Leu99 of thrombin in determining the P2 specificity of serpins. Rezaie AR Biochemistry; 1997 Jun; 36(24):7437-46. PubMed ID: 9200692 [TBL] [Abstract][Full Text] [Related]
12. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Derechin VM; Blinder MA; Tollefsen DM J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609 [TBL] [Abstract][Full Text] [Related]
13. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant. Hamada M; Bhakta V; Andres SN; Sheffield WP Front Cardiovasc Med; 2021; 8():647405. PubMed ID: 33816577 [TBL] [Abstract][Full Text] [Related]
14. Contribution of lysine 60f to S1' specificity of thrombin. Rezaie AR; Olson ST Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392 [TBL] [Abstract][Full Text] [Related]
15. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity. Bhakta V; Gierczak RF; Sheffield WP J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600 [TBL] [Abstract][Full Text] [Related]
16. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin. Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770 [TBL] [Abstract][Full Text] [Related]
17. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures. Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease. Stone SR; Le Bonniec BF J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]